Kras Tcr-Transduced Pbl
Malignant Urinary System Neoplasm
Explore 15 assets in Malignant Urinary System Neoplasm →Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
National Cancer Institute (NCI)
Modality
Cell therapy
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06253520CT.gov Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Malignant Urinary System Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Kras Tcr-Transduced Pbl (this asset) | National Cancer Institute (NCI) | P1 | CC · 43 |
| Tadalafil | Regina Elena Cancer Institute | P3 | B |
| Nivolumab | Spanish Oncology Genito-Urinary Group | P2 | B |
| Ipilimumab | Dana-Farber Cancer Institute | P2 | B |
| Atezolizumab | British Columbia Cancer Agency | P2 | B |
| Amcasertib | Sumitomo Pharma America, Inc. | P2 | CCC |
| Riluzole | University of California, Irvine | P2 | CCC |
| Adriamycin | University of Illinois at Chicago | P1 | CCC |
| Pazopanib | University of Illinois at Chicago | P1 | CC |
+21 more in the Malignant Urinary System Neoplasm cohort
Other indications for Kras Tcr-Transduced Pbl
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Metastatic Malignant Neoplasm | — | P2 | B · 59 |
| Hepatocellular Carcinoma | — | P2 | CCC · 53 |
| Digestive System Carcinoma | — | P2 | CCC · 53 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Kras Tcr-Transduced Pbl in Malignant Urinary System Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/kras-tcr-transduced-pbl-malignant-urinary-system-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →